Title :

Utility of (18)fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma

Author(s) :

Horwitz, SM [Auteur]
Memorial Sloan Kettering Cancer Center [MSKCC]
Coiffier, Bertrand [Auteur]
Hospices Civils de Lyon, Departement de Neurologie [HCL]
Foss, FM [Auteur]
Prince, HM [Auteur]
Peter Mac Callum Cancer Centre
Sokol, L [Auteur]
H. Lee Moffitt Cancer Center and Research Institute
Greenwood, M [Auteur]
Royal North Shore Hospital [RNSH]
Caballero, Dolores [Auteur]
Universidad de Salamanca
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Pinter-Brown, L [Auteur]
Harbor UCLA Medical Center [Torrance, Ca.]
Iyer, SP [Auteur]
Houston Methodist Hospital [Houston, TX, USA]
Shustov, A [Auteur]
University of Washington [Seattle]
Nichols, J [Auteur]
University of Liverpool
Balser, J [Auteur]
Balser, BE [Auteur]
Pro, B [Auteur]
Jefferson University Hospitals

Journal title :

Annals of oncology

Abbreviated title :

Ann. Oncol.

Volume number :

26

Pages :

774-779

Publication date :

2015-04-26

ISSN :

1569-8041

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The ...
Show more >BACKGROUND: For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The utility of FDG-PET, in addition to conventional radiology, was examined as a planned exploratory end point in the pivotal phase 2 trial of romidepsin for the treatment of relapsed/refractory PTCL. PATIENTS AND METHODS: Patients received romidepsin at a dose of 14 mg/m(2) on days 1, 8, and 15 of 28-day cycles. The primary end point was the rate of confirmed/unconfirmed complete response (CR/CRu) as assessed by International Workshop Criteria (IWC) using conventional radiology. For the exploratory PET end point, patients with at least baseline FDG-PET scans were assessed by IWC + PET criteria. RESULTS: Of 130 patients, 110 had baseline FDG-PET scans, and 105 were PET positive at baseline. The use of IWC + PET criteria increased the objective response rate to 30% compared with 26% by conventional radiology. Durations of response were well differentiated by both conventional radiology response criteria [CR/CRu versus partial response (PR), P = 0.0001] and PET status (negative versus positive, P < 0.0001). Patients who achieved CR/CRu had prolonged progression-free survival (PFS, median 25.9 months) compared with other response groups (P = 0.0007). Patients who achieved PR or stable disease (SD) had similar PFS (median 7.2 and 6.3 months, respectively, P = 0.6427). When grouping PR and SD patients by PET status, patients with PET-negative versus PET-positive disease had a median PFS of 18.2 versus 7.1 months (P = 0.0923). CONCLUSIONS: Routine use of FDG-PET does not obviate conventional staging, but may aid in determining prognosis and refine response assessments for patients with PTCL, particularly for those who do not achieve CR/CRu by conventional staging. The optimal way to incorporate FDG-PET scans for patients with PTCL remains to be determined. TRIAL REGISTRATION: NCT00426764.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Research team(s) :

Innovation/évaluation des médicaments injectables

Submission date :

2019-02-26T17:07:42Z
2021-06-21T09:44:27Z